The state of Virginia currently has 420 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Richmond, Charlottesville, Norfolk and Fairfax.
Study of XB010 in Subjects With Solid Tumors
NCT06545331
Recruiting
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Exelixis Clinical Site #2, Fairfax, Virginia
Conditions: Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Register for Updates
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
NCT06315491
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Virgina Cancer Specialist, Fairfax, Virginia
Conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
NCT06707610
Recruiting
TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/09/2025
Locations: Next Oncology, Fairfax, Virginia
Conditions: Advanced Cancer, Advanced Solid Tumor
Register for Updates
Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
NCT05334732
Recruiting
The purpose of this study is to test an evidence-based intervention designed to increase adherence to systemic therapy in Black women compared to enhanced usual care.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Massey Cancer Center, Richmond, Virginia
Conditions: Breast Cancer
Register for Updates
Safety Study for a Gamma Delta T Cell Product Used with Low Dose Radiotherapy in Patients with Locally Advanced or Metastatic NSCLC or Solid Tumors with Bone Metastases
NCT06069570
Recruiting
This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Virginia Oncology Associates, Norfolk, Virginia
Conditions: Carcinoma, Non-Small-Cell Lung Cancer, Bone Metastases from Solid Tumors
Register for Updates
A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NCT06234423
Recruiting
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Ovarian Cancer, Solid Tumor
Register for Updates
Repositioning Immunotherapy in VetArans With Lung Cancer
NCT06275360
Recruiting
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
NCT06237179
Recruiting
To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak \& 6-minute walk distance \[6MWD\]) among prostate cancer (PC) patients compared to controls receiving healthy living education (HLE) at 12 weeks.
Gender:
MALE
Ages:
Between 40 years and 85 years
Trial Updated:
02/26/2025
Locations: Richmond Veterans Affairs Medical Center, Richmond, Virginia +1 locations
Conditions: Prostate Cancer, Supportive Care
Register for Updates
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
NCT06139458
Recruiting
The investigators aim to determine the effect of cryotherapy wraps plus compression therapy (henceforth referred to as cryocompression) versus cryotherapy wraps alone on the incidence and degree of chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer using a noninferiority design. The investigators also aim to determine the effect of cryocompression versus cryotherapy on patient tolerability and patient and staff satisfaction.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Carilion Clinic, Roanoke, Virginia
Conditions: Gynecologic Cancer, Chemotherapy-induced Peripheral Neuropathy
Register for Updates
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
NCT05653882
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth, Richmond, Virginia
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Register for Updates
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971
Recruiting
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Cancer Specialists, PC, Fairfax, Virginia
Conditions: Small Cell Lung Cancer Extensive Stage
Register for Updates
Health Education Approach to Lung Screening
NCT06070870
Recruiting
Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Lung Cancer
Register for Updates